Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
|Articles|July 23, 2021
Clinical Pearl of the Day: SGLT2 Inhibitors and Glomerular Filtration Rate Cutoffs
Author(s)Saro Arakelians, PharmD
Listen
0:00 / 0:00
Key Takeaways
- SGLT2 inhibitors' efficacy is dependent on GFR, as they rely on glucose filtered load for action.
- Empagliflozin and canagliflozin should be discontinued if GFR falls below 30.
Below a certain GFR, clinically significant reductions in plasma glucose cannot be achieved with sodium-glucose transport protein 2 inhibitors.
Advertisement
Sodium-glucose transport protein 2 (SGLT2) inhibitors and glomerular filtration rate cutoffs:
- On empagliflozin (Jardiance) and GFR is below 30, empagliflozin should be discontinued.
- On dapagliflozin (Farxiga) and GFR is below 45, dapagliflozin should be discontinued.
- On canagliflozin (Invokana) and GFR is below 30, canagliflozin should be discontinued.
Explanation:
Given their mode of action, which is heavily dependent on the glucose filtered load and therefore on GFR, the efficacy of SGLT2 inhibitors in reducing plasma glucose is expected to be decreased with decreasing renal function.
Below a certain GFR, clinically significant reductions in plasma glucose cannot be achieved with SGLT2s.
References
Advertisement
Related to this article
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
3
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
4
Amivantamab Becomes First FDA-Approved Therapy in 10 Years for Pretreated Recurrent or Metastatic HNSCC
5